Patents by Inventor Donald Wilton

Donald Wilton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
    Publication number: 20200231966
    Abstract: Antisense agents and RNA interference agents useful for treating diseases and conditions the treatment of which can benefit from reducing the expression of double homeobox 4 and/or double homeobox 4c, more particularly facioscapulohumeral muscular dystrophy. Methods, uses and further products employing such agents are also described.
    Type: Application
    Filed: September 5, 2019
    Publication date: July 23, 2020
    Inventors: Alexandra Belayew, Frederique Coppee, Celine Vanderplanck, Stephen Donald Wilton, Eugenie Ansseau
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20200199590
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: July 31, 2019
    Publication date: June 25, 2020
    Applicant: The University of Western Australia
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Graham MCCLOREY
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20190323010
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Application
    Filed: July 1, 2019
    Publication date: October 24, 2019
    Applicant: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Restoration of the CFTR function by splicing modulation
    Patent number: 10428328
    Abstract: Oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, compositions including the oligonucleotides, kits including the compositions, and uses thereof. Compositions of oligonucleotides useful in methods for suppressing exon 10 skipping optionally in combination with additional CFTR therapeutics.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: October 1, 2019
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Batsheva Kerem, Michal Tur Sinai, Loren Price, Stephen Donald Wilton, Sue Fletcher
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 10421966
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: September 24, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
    Publication number: 20190270994
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 5, 2019
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Abbie ADAMS, Penny MELONI
  • Multiple sclerosis treatment
    Patent number: 10376536
    Abstract: An antisense oligomer capable of binding to a selected target on the ITGA4 gene transcript to modify pre-mRNA splicing in an ITGA4 gene transcript or part thereof.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 13, 2019
    Assignee: MURDOCH UNIVERSITY
    Inventors: Stephen Donald Wilton, Sue Fletcher, May Aung-Htut
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20190144861
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: January 22, 2019
    Publication date: May 16, 2019
    Applicant: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 10266827
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: April 23, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 10227590
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: March 12, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20190062742
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 28, 2019
    Applicant: The University of Western Australia
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Graham MCCLOREY
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20180371458
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 27, 2018
    Applicant: The University of Western Australia
    Inventors: Stephen Donald WILTON, Sue Fletcher, Graham McClorey
  • AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
    Publication number: 20180265870
    Abstract: The invention teaches antisense agents and RNA interference agents useful for treating diseases and conditions the treatment of which can benefit from reducing the expression of double homeobox 4 and/or double homeobox 4c, more particularly facioscapulohumeral muscular dystrophy. Further elaborated are methods, uses and further products employing such agents.
    Type: Application
    Filed: January 17, 2018
    Publication date: September 20, 2018
    Inventors: Alexandra Belayew, Frederique Coppee, Celine Vanderplanck, Stephen Donald Wilton, Eugenie Ansseau
  • ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE
    Publication number: 20180216111
    Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for inducing exon inclusion as a treatment for glycogen storage disease type II (GSD-II) (also known as Pompe disease, glycogenosis II, acid maltase deficiency (AMD), acid alpha-glucosidase deficiency, and lysosomal alpha-glucosidase deficiency), and more specifically relates to inducing inclusion of exon 2 and thereby restoring levels of enzymatically active acid alpha-glucosidase (GAA) protein encoded by the GAA gene.
    Type: Application
    Filed: February 29, 2016
    Publication date: August 2, 2018
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Gunnar James HANSON, Richard Keith BESTWICK, Frederick J. SCHNELL
  • ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
    Publication number: 20180171333
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
    Type: Application
    Filed: July 27, 2017
    Publication date: June 21, 2018
    Inventors: Stephen Donald Wilton, Sue Fletcher, Abbie Adams, Penny Meloni
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20180163205
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Application
    Filed: August 9, 2017
    Publication date: June 14, 2018
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Graham MCCLOREY
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 9994851
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: June 12, 2018
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: RE47691
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 5, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: RE47751
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 3, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: RE47769
    Abstract: Antisense molecules capable of binding to a selected target site in the dystrophin gene to induce exon skipping are described.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 17, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey